Quarterly ResultMay 13, 2026, 04:12 PM
Equillium Q1 Net Loss $(5.3)M; Appoints New CDO
AI Summary
Equillium reported a reduced net loss of $(5.3) million for the first quarter ended March 31, 2026, compared to $(8.7) million in the same period last year, with R&D and G&A expenses decreasing. The company's cash and cash equivalents significantly increased to $61.3 million, extending its operational runway into 2029, partly due to a $35 million private placement. Additionally, Equillium appointed Snehal Naik, Ph.D., as Chief Development Officer and confirmed that its Phase 1 study for EQ504 is on track for mid-2026 initiation.
Key Highlights
- Net loss for Q1 2026 was $(5.3) million, an improvement from $(8.7) million in Q1 2025.
- Net loss per share improved to $(0.06) in Q1 2026 from $(0.24) in Q1 2025.
- Research and development expenses decreased to $3.0 million in Q1 2026 from $5.9 million in Q1 2025.
- General and administrative expenses decreased to $2.6 million in Q1 2026 from $2.9 million in Q1 2025.
- Cash and cash equivalents totaled $61.3 million as of March 31, 2026, up from $30.3 million at year-end 2025.
- Cash and cash equivalents are expected to fund planned operations into 2029.
- Snehal Naik, Ph.D., was appointed as Chief Development Officer.
- Phase 1 proof-of-mechanism study of EQ504 is on track to initiate in mid-2026.
Price Impact
More from EQ